An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor

Journal of Steroid Biochemistry and Molecular Biology

Volumn 58, Issue 5-6, 1996, Pages 479-488

  Bilimoria, Malcolm M ^a   Assikis, Vasilios J ^a   Muenzner, Henry D ^a   Wolf, Douglas M ^b   Satyaswaroop, Pondichery G ^c   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINK CELL FOCUS-FORMING VIRUS;

ANTIESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN;

ARTICLE; CARCINOMA; DNA SEQUENCE; DRUG ANTAGONISM; DRUG EFFECT; ENDOMETRIUM TUMOR; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HUMAN; METABOLISM; MUTATION; OVARY TUMOR;

CARCINOMA; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MUTATION; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; SEQUENCE ANALYSIS, DNA; TAMOXIFEN;

EID: 0030203362     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(96)00078-7     Document Type: Article

References (38)

1. Morrow M. and Jordan V. C.: Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. Arch. Surg. 128 (1993) 1187-1191.
2. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339 (1992) 1-15, 71-85.
3. Nayfield S. G., Karp J. E., Ford L. G., Dorr A. and Kramer B. S.: Potential role of tamoxifen in prevention of breast cancer. J. Natn. Cancer Inst. 83 (1991) 1450-1459.
4. Maas H., Jonat W., Stolzenbach G. and Trams G.: The problem of nonresponding estrogen-receptor positive patients with advanced breast cancer. Cancer 6 (1980) 2835-2837.
5. Jiang S. Y., Langan-Fahey S. M., Stella A. L., McCague R. and Jordan V. C.: Point mutation of estrogen receptor (ER) in the ligand binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing cDNAs for ER. Molec. Endocr. 6 (1992) 2167-2174.
6. Kumar V. and Chambon P.: The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55 (1988) 145-156.
7. Tsai S. Y., Carlstedt-Duke J., Weigel N. L., Dahlman K., Gustafsson J. A., Tsai M. J. and O'Malley B. W.: Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell 55 (1988) 361-369.
8. Kumar V., Green S., Stack G., Berry M., Jin J. R. and Chambon P.: Functional domains of the human estrogen receptor. Cell 51 (1987) 941-951.
9. Webster N. J., Green S., Jin J. R. and Chambon P.: The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54 (1988) 199-207.
10. Hard T., Kellenbach E., Boelens R., Maler B. A., Dahlman K., Freedman L. P., Carlstedt-Duke J., Yamamoto K. R., Gustafsson J. A. and Kaptein R.: Solution structure of the glucocorticoid receptor DNA-binding domain. Science 249 (1990) 157-160.
11. Evans R. M.: The steroid and thyroid hormone receptor superfamily. Science 240 (1988) 889-895.
12. Picard D. and Yamamoto K. R.: Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO J. 6 (1987) 3333-3340.
13. Danielian P. S., White R., Lees J. A. and Parker M. G.: Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J. 11 (1992) 1025-1033.
14. Lees J. A., Fawell S. E. and Parker M. G.: Identification of two transcriptional domains in the mouse oestrogen receptor. Nucl. Acids Res. 17 (1989) 5477-5488.
15. Mahfoudi A., Roulet E., Dauvois S., Parker M. G. and Wahli W.: Specific mutations in the estrogen receptor change the properties of an antiestrogen to full agonists. Proc. Natn. Acad. Sci. U.S.A. 92 (1995) 4206-4210.
16. Gottardis M. M. and Jordan V. C.: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48 (1988) 5183-5187.
17. Satyaswaroop P. G., Zaino R. J. and Mortel R.: Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res. 44 (1984) 4006-4010.
18. Wolf D. M. and Jordan V. C.: Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res. Treat. 31 (1994) 117-127.
19. Wolf D. M. and Jordan V. C.: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat. 31 (1994) 129-138.
20. Gottardis M. M., Robinson S. P., Satyaswaroop P. G. and Jordan V. C.: Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen stimulated human endometrial carcinoma (EnCa 101) in athymic mice. Cancer Res. 50 (1990) 3189-3192.
21. Clarke C. L. and Satyaswaroop P. G.: Photoaffinity labelling of the progesterone receptor from human endometrial carcinoma. Cancer Res. 45 (1985) 5417-5420.
22. Anzai Y., Holinka C. F., Kuramoto H. and Gurpide E.: Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res. 49 (1989) 2362-2365.
23. Chomczynski P. and Sacchi N.: Single-step method of RNA isolation by acid-guanidinium thiocyanate-phenol-chloroform extraction. Analyt. Biochem. 162 (1987) 156-159.
24. Chung C. T. and Miller R. H.: A rapid and convenient method for the preperation and storage of competent bacterial cells. Nucl. Acids Res. 16 (1988) 3580.
25. Wolf D. M. and Jordan V. C.: A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res. 127 (1993) 23-33.
26. Wolf D. M. and Jordan V. C.: Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Res. Treat. 27 (1993) 27-40.
27. Wiebe V. J., Osborne C. K., McGuire W. L. and DeGregorio M.: Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J. Clin. Oncol. 10 (1992) 990-994.
28. Wolf D. M., Langan-Fahey S. M., Parker C. J., McCague R. and Jordan V. C.: Investigation of the mechanisms of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J. Natn. Cancer Inst. 85 (1993) 806-812.
29. Trichopoulos D., MacMahon B. and Cole P.: Menopause and breast cancer risk. J. Natn. Cancer Inst. 48 (1972) 605-607.
30. Clarke R., Brunner N., Katzenellenbogen B. S., Thompson E. W., Norman M. J., Koppi C., Paik S., Lippman M. E. and Dickson R. B.: Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc. Natn. Acad. Sci. U.S.A. 86 (1989) 3649-3653.
31. Murphy C. S., Pink J. J. and Jordan V. C.: Characterization of a receptor-negative, hormone non-responsive clone derived from T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res. 50 (1990) 7285-7292.
32. Jiang S. Y. and Jordan V. C.: Growth regulation of estrogen receptor negative breast cancer cells transfected with cDNAs for estrogen receptor. J. Natn. Cancer Inst. 84 (1992) 580-591.
33. Catherino W. H., Wolf D. M. and Jordan V. C.: A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Molec. Endocr. 9 (1995) 1053-1063.
34. Condie A., Eales R., Borresen A., Coles C., Cooper C. and Prosser J.: Detection of point mutations in the p53 gene: comparison of single stranded conformational polymorphism, constant denaturant gel electrophoresis and hydroxylamine and osmium tetroxide techniques. Human Mut. 2 (1993) 58-66.
35. Gottardis M. M., Jiang S. Y., Jeng M. H. and Jordan V. C.: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 49 (1989) 4090-4093.
36. Lerner L. J. and Jordan V. C.: Development of antiestrogens and their use in breast cancer: eighth Cain Memorial Award Lecture. Cancer Res. 50 (1990) 4177-4189.
37. Howell A., Defriend D., Robertson J., Blarney R. and Walton P.: Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 345 (1995) 29-30.
38. Fuqua S. A. W., Fitzgerald S. D., Chamness G. C., Tandon A. K., McDonnell D. P., Nawaz Z., O'Malley B. W. and McGuire W. L.: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 41 (1991) 105-109.